Beijing G-D Biotechnology

Beijing G-D Biotechnology is a clinical-stage biopharmaceutical company focused on the development of innovative oncolytic virus therapies for oncology. The company leverages its proprietary engineering platform to create recombinant viruses designed to selectively infect and lyse tumor cells while inducing a robust systemic immune response. Its lead program, GD-101, is a genetically modified herpes simplex virus type 1 (oHSV-1) currently being evaluated in clinical trials for advanced solid tumors. Beyond its lead asset, the company is advancing a pipeline of next-generation oncolytic candidates with enhanced targeting and immune-stimulating capabilities. Beijing G-D Biotechnology aims to provide transformative treatment options for patients with refractory cancers through its expertise in viral vector engineering and immunotherapy.